Back to UBS Group AG UBS Group AG

PYXSPYXS
Showing 8 of 19 quarters

Position history for UBS Group AGUBS Group AG's holdings in PYXIS ONCOLOGY INC

Yes. Ubs holds 155,217 shares of PYXS (Pyxis Oncology), worth $467,203, as of its Q2 2026 13F filing. It reduced the position by 98,907 shares (-38.9%) from Q1 2026. Ubs has held PYXS since Q1 2023, across 14 quarterly 13F filings.

Current Value

$467,203

Current Shares

155,217

Total Value Change

+$364,069

Total Shares Change

+127,115

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
155,217
-38.9%
$467,2030.0%$3.01
0
2026-Q1
Decreased
254,124
-35.3%
$371,0210.0%$1.43
0
2025-Q4
Increased
392,766
+5.1%
$451,6810.0%$1.09
25
2025-Q3
Decreased
373,727
-5.7%
$829,6740.0%$2.20
0
2025-Q2
Decreased
396,096
-0.2%
$435,7060.0%$1.10
0
2025-Q1
Decreased
396,844
-11.2%
$388,9080.0%$1.06
0
2024-Q4
Increased
446,699
+1489.6%
$696,8510.0%$1.56
40
2024-Q3
Increased
28,102
+59.0%
$103,1340.0%$3.62
21

Other major holders of PYXS: RA CAPITAL MANAGEMENT, L.P., RTW INVESTMENTS, LP, CITADEL ADVISORS LLC, Janus Henderson Group Ltd., BALYASNY ASSET MANAGEMENT L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used